Skip to main content
OpenTrials
Completed

NCT Number: NCT02455180

Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients

The purpose of this study is to determine the pharmacokinetic properties of two different dosage regimens of intravenous vitamin C in patients admitted to the Intensive Care Unit with life-threatening illness.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

VU University Medical Center

Amsterdam, 1081 HV, Netherlands

About this study

Rationale:

Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of admission. Vitamin C is a natural anti-oxidant and crucial for endothelial and organ protection

Objective:

To determine the pharmacokinetics of two high dose regimens of intravenous vitamin C in critically ill patients, in particular the attained plasma concentration and the fraction retained in the body and excreted in urine.

Study design:

Prospective randomized controlled pharmacokinetic intervention study

Study population:

Adult critically ill patients admitted to the ICU of the VU University Medical Center, Amsterdam, with sepsis or SIRS after major surgery or trauma with a non-neurological sequential organ failure (SOFA) score >6 and an expected length of ICU stay of >96 hours.

Intervention (if applicable):

Patients will receive either 2 or 10 gram/day vitamin C intravenously twice daily for two days in bolus or continuous infusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sepsis or Systemic Inflammatory Response Syndrome (SIRS) after major surgery or trauma;
  • Non-neurological sequential organ failure assessment (SOFA) score >6;
  • Expected length of ICU stay > 96 hours;
  • Written proxy consent by legal representative.

Exclusion criteria

  • Admission after out of hospital cardiac arrest
  • Prior use of supplemental vitamin C in the week before
  • Major bleeding
  • Pre-existent renal insufficiency defined as an eGFR of < 30 ml/min/1.73 m2 (stadium 4-5)
  • Expected need for renal replacement therapy within 48 hours
  • Known glucose 6-phosphate dehydrogenase deficiency
  • History of urolithiasis or oxalate nephropathy
  • Previous use of prolonged high dose vitamin C supplements
  • Hemochromatosis

Treatment and study plan

ascorbic acid

Drug

Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.

Other names: Vitamin C

Primary outcomes

  1. Vitamin C plasma concentration

    Time frame: Baseline (before intervention), thereafter at 1, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours after first intervention

  2. Vitamin C excreted in urine

    Time frame: 0-12hours after first intervention; 36-48 hours after first intervention

Secondary outcomes

  1. Oxalate excretion in urine

    Time frame: 0-12hours after first intervention; 36-48 hours after first intervention

  2. F2-isoprostanes (oxidative damage biomarker)

    Time frame: 0, 24 and 72 hours after first intervention

  3. CellROX (reactive oxygen species activity in leukocytes)

    Time frame: 0 and 24 hours after first intervention

  4. Vasopressor requirements (noradrenalin dose)

    Time frame: 0, 12, 24, 48, 72 and 96 hours after first intervention

  5. Renal resistive index (ultrasonography)

    Time frame: 0, 4, 24, 72 hours after first intervention

  6. Serum creatinine and creatinine clearance

    Time frame: 0, 24, 48, 72, 95 after first intervention

  7. Sequential Organ Failure Assessment (SOFA) score

    Time frame: 0, 24, 48, 72, 95 after first intervention

Sponsors and collaborators

Lead sponsor

Amsterdam UMC, location VUmc

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
May 27, 2015
Registry last updated
Aug 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.